A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
Initial Purchase by Beijing Dahua Sanxin Technology Development Co., Ltd. Represents First MiOXSYS Commercial Sale in China. ENGLEWOOD, CO / June 4, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel...
ENGLEWOOD, CO / May 21, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that MiOXSYS®, the company's first-in-class seminal oxidative...
Company Posts Highest Ever Quarterly Revenue ENGLEWOOD, CO / May 14, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today will provide an overview of its...
Live Conference Call and Webcast Scheduled for May 14, 2019, at 9:00 a.m. ET ENGLEWOOD, CO / May 7, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today...
ENGLEWOOD, Colo., March 7, 2018 -- Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that it has received registration in Mexico for the MiOXSYS...
ENGLEWOOD, Colo., March 6, 2018 -- Aytu BioScience, Inc. (NASDAQ: AYTU) (the "Company"), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced the closing of its previously announced...
ENGLEWOOD, Colo., March 1, 2018 -- Aytu BioScience, Inc. (NASDAQ: AYTU) (the "Company"), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced the pricing of an underwritten public offering...
ENGLEWOOD, Colo., Feb. 21, 2018 Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today provided an update on the ongoing launch of Natesto in the U.S. Robust Natesto...
Natesto prescriptions increased 23% over previous quarter, and 317% over the same quarter last yearENGLEWOOD, Colo., Feb. 8, 2018 -- Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the...
Live Conference Call and Webcast Scheduled for February 8, 2018, at 4:30 p.m. ETENGLEWOOD, Colo., Feb. 1, 2018 -- Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology,...